PTPN3 and prostate adenocarcinoma: Our analysis of DFS demonstrated that among patients with LUSC (p = 0.011), a poor DFS showed in those with high levels of PTPN3 expression; by contrast, in patients with PRAD (p = 0.023), high PTPN3 expression levels were associated with good DFS (Fig. 5B).